Healthy subjects
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Males aged 30 to 49 years when informed consent. 2. Subjects who work within office buildings. 3. Subjects who receive enough explain of the test, who deeply understanding of the test, and who obtain own consent to participate the test.
Exclusion criteria
Exclusion criteria: 1. Subjects who tested positive for SARS-CoV-2 before the screening, who tested positive for hepatitis B virus, hepatitis C virus, syphilis and human immunodeficiency virus in the screening. 2. Subjects who themselves or family living together tested positive for SARS-CoV-2, or have a fever of 37.5 degrees or higher within the last four weeks. 3. Subjects who are planning to receive the COVID-19 vaccine during the trial. 4. Subjects who have diseases which are difficult to differentiate from upper respiratory infection by themselves. 5. Subjects who have abdominal symptoms by ingesting dairy products. 6. Subjects who constantly intake fermented dairy products and/or lactic acid bacteria preparation. 7. Subjects who constantly use food for specified health use, functional foods, supplements, and/or healthy food having a possibility of affecting the result of this trial. 8. Subjects who have previous and/or current medical history of serious disease. 9. Subjects who with heavy use of alcohol, and heavy smoking. 10. Subjects who have extremely irregular dining habits. 11. Subjects who are participating the other clinical tests, who participated the other clinical tests within 4-weeks prior to the current study. 12. Subjects who have previous medical history of drug and/or food, allergy, especially for milk and soy. 13. Subjects who donated over 200mL blood and/or blood components within the last one month. 14. Subjects who donated over 400mL blood and/or blood components within the last three month. 15. Subjects who will be collected over 1200mL blood and/or blood components, when the sampling amounts within the last twelve month are adding to the planned sampling amounts of this study. 16. Others who have been determined ineligible by principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immunity index | — |
Countries
Japan
Contacts
CPCC Company Limited Planning & Sales Department